deltatrials
Completed PHASE2 NCT00047814

Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

A Multiple Rising-Dose Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

Sponsor: Astellas Pharma Inc

Conditions Hepatitis C
Interventions FK788
Updated 5 times since 2017 Last updated: Dec 8, 2011 Started: Oct 31, 2002 Completion: Mar 31, 2006

This PHASE2 trial investigates Hepatitis C and is currently completed. Astellas Pharma Inc leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astellas Pharma Inc
  • Astellas Pharma US, Inc.
Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations